Recaída de enfermedad entre pacientes hispanos lúpicos con enfermedad renal crónica en hemodiálisis. Presentación de casos

Percy Herrera Añazco, Percy Velasquez-Castillo, Luis Arellán-Bravo

Texto completo:

HTML PDF

Resumen

Introducción: Los pacientes con lupus eritematoso sistémico (LES) presentan una disminución de la actividad de la enfermedad cuando evoluciona a una enfermedad renal crónica (ERC). Se han publicado recaídas de LES en esta etapa en diferentes grupos étnicos, aunque no pacientes hispanos, tradicionalmente asociados a peor pronóstico.

Objetivo: Describir los casos de pacientes con ERC en hemodiálisis con diagnóstico de recaída de la enfermedad.

Presentación de casos: Se presentan 4 casos, 2 varones y 2 mujeres con una edad promedio de 28 años. Tuvieron un promedio de score de SLEDAI sin criterios renales de 20.25, quienes presentaron exacerbaciones de diferentes características. Todos recibieron tratamiento inmunosupresor y fallecieron 2 pacientes.

Conclusiones: Nuestro sistema de salud debería establecer estrategia de seguimiento adecuado a estos pacientes con evaluaciones frecuentes de la actividad de su enfermedad de tal forma que permita hacer un diagnóstico y tratamiento temprano. Nuestro sistema de salud debe instaurar medidas de seguimiento de los pacientes con LES en hemodiálisis para el diagnóstico y tratamiento temprano de las recaídas por LES.

Palabras claves: Lupus eritematosos sistémico, diálisis renal, recurrencia, pronóstico.

Palabras clave

Lupus eritematosos sistémico, diálisis renal, recurrencia, pronóstico

Referencias

Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) [Internet]. 2017 Nov [cited 23/08/2019]; 56(11):1945-1961. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kex260

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis [Internet]. 2016 [cited 23/08/2018] Jan; 75(1):136-41. Available from: https://ard.bmj.com/content/75/1/136.long

Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. [Internet]. 2012 [cited 23/08/2018]; 27(8):3248–54. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs073

Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci[internet] 2013 [cited 23/08/2018]; 346(4):319–23. Available from: https://www.amjmedsci.org/article/S0002-9629 (15)30521-8/fulltext

Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol [Internet]. 2013 Jan-Feb [cited 23/08/2018]; 31(1):31-9. Disponible en: http://www.clinexprheumatol.org/abstract.asp?a=5501

Barrera-Vargas A, Quintanar-Martínez M, Merayo-Chalico J, Alcocer-Varela J, Gómez-Martín D. Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case-control study. Rheumatology (Oxford). [Internet]. 2016 Mar [cited 23/08/2018]; 55(3):429-35. Available from https://academic.oup.com/rheumatology/articlelookup/doi/10.1093/rheumatology/kev349

Kaul H, Girndt M, Sester U, Sester M, Kohler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis [Internet]. 2000 [cited 23/08/2018]; 35 (4):611–16. Available from: ttps://www.ajkd.org/article/S0272-6386(00h)70006-0/fulltext

Mejía-Vilet JM, Córdova-Sánchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe N. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. [Internet]. 2016 Mar [cited 23/08/2018]; 25(3):315-24. Available from: https://journals.sagepub.com/doi/abs/10.1177/0961203315606985?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=lupa

Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephron [Internet] 2014 Feb [cited 23/08/2018]; 9(2):279-84. Available from: https://cjasn.asnjournals.org/content/9/2/279.long

Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr [Internet]. 2012 [cited 23/08/2018]; 22(1):149-56. Disponible en: https://www.jrnjournal.org/article/S1051-2276(11)00210-X/fulltext

Althaf MM, Abdelsalam MS, Alfurayh OI. Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy– case series. Lupus. [Internet]. 2014 Aug [cited 23/08/2018]; 23(9):945-8. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0961203314530487?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=lupa

Mattos P, Mittermayer BS. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literatura. Clin Rheumatol [Internet]. 2012 Jun [citado 23/08/2018]; 31(6):897-905. Disponible en: https://link.springer.com/article/10.1007%2Fs10067-012-1957-9

Contreras G, Lenz O, Pardo V, Borja E, Cely C. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int [Internet]. 2006 [cited 23/08/2018]; 69(10):1846-51. Available from: https://www.kidney-international.org/article/S0085-2538(15)51340-9/fulltext

Pahl MV, Gollapudi S, Sepassi L Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant [Internet]. 2010 [cited 23/08/2018]; 25(1):205-12. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfp397

Lim WH, Kireta S, Russ GR, Coates PT. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int [internet] 2007 [citado 23/08/2018]; 71(11):1122-31. Disponible en: https://www.kidney-international.org/article/S0085-2538(15)52275-8/fulltext

Cucchiari D, Graziani G1, Ponticelli C. The dialysis scenario in patients with systemic lupus erythematosus. Neph Dial Transp. [Internet]. 2014 Aug [cited 23/08/2018];29(8):1507-1513. Available from: https://academic.oup.com/ndt/article/29/8/1507/1938224

Ribeiro FM, Leite MA, Velarde GC, Fabris CL, Santos RC. Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol. [Internet]. 2005 [cited 23/08/2018]; 25(6):596–603. Available from: https://www.karger.com/Article/Abstract/89708

Kang SH, Chung BH, Choi SR, Lee JY, Park HS, In-O S. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med [Internet]. 2011 [cited 23/08/2018]; 26(1):60-67. Available from: http://kjim.org/journal/view.php?doi=10.3904/kjim.2011.26.1.60

Nossent HC, Swaak TJ, Berden JH: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on LES. Am J Med [Internet].1990 [citado 23/08/2018]; 89(2): 169–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2382665

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum [internet] 1992 [cited 23/08/2018]; 35(6):630–640. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.1780350606?sid=nlm%3Apubmed

Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Mengozzi G, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol [Internet]. 2005 [cited 23/08/2018]; 18(3): 282–288. Disponible en: https://www.researchgate.net/publication/7731673_Procalcitonin_as_a_marker_of_micro-inflammation_in_hemodialysis

Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ, et al. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev [Internet]. 2012 [citado 23/08/2018]; 12(2): 157–163. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1568997212000791?via%3Dihub

Broder A, Khattri S, Patel R, Putterman C. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol [Internet]. 2011 [cited 23/08/2018]; 38(11): 2382–2389. Available from: http://www.jrheum.org/content/38/11/2382.long

Lewis MJ, Jawad A. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford). [Internet]. 2017 Apr [internet]; 56(suppl_1):i67-i77. Disponible en: https://academic.oup.com/rheumatology/article/56/suppl_1/i67/2629213

Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. [Internet]. 2018 [citado 23/08/2018]; 14(18):1043-1053. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/1744666X.2018.1538789?journalCode=ierm20

Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore). [Internet]. 2004 Jan [citado 23/08/2018]; 83(1):1-17. Disponible en: https://insights.ovid.com/pubmed?pmid=14747764



Añadir comentario